Abstract 421P
Background
Tumors deficient in DNA repair mechanism, particularly the HRR including BRCA (somatic and /or germline ) are sensitive to Platinum chemotherapy, PARP inhibitors (PARPi), and immunotherapy (IO) in cancers like breast and ovarian, however, clinical trials are ongoing in pancreatic, prostate, endometrial and other cancer types which have progressed on first-line chemotherapy. In this study, CGP identified the landscape of sBRCA and HRR as potential biomarkers across the multi-cancer cohort.
Methods
950 biopsy proven patient samples at HCG were profiled using Illumina TruSight Oncology 500 assay on NextSeq2000 in an IRB-approved study. Sequenced data was processed by StrandOmics platform.
Results
About 142 (15 %) patients in the studied cohort of multiple cancer types were found with alterations in sBRCA and HRR pathway. 208 mutations were detected across 950 cases with 66 cases reporting ≥ 1 HRR gene alterations (mean incidence of 1.4/case). 37 HRR cases were associated with elevated tumor mutation burden. sBRCA1 and sBRCA2 were found in 22 and 27 patients respectively accounting for 3% HRR pathway. Other HRR genes included ATM, RAD51, PTEN, ATRX, PALB2, MRE11A, RAD50, CDK12, ARID1A and PTEN in 12 % of HRR pathway. It is noteworthy that sBRCA and HRR gene alterations were found across diverse cancers, highest in gastrointestinal followed by breast cancer (TNBC-56%) (Table). Apart from FDA approved cancers (n=57), HRR alteration were prevalent across other diverse cancers (n=85) in the cohort. 60% patients with sBRCA and HRR mutations treated with platinum / PARPi as NACT, achieved partial to pathological complete response (pCR) while 5 cases treated with IO are on follow up. Table: 421P
Prevalence of sBRCA and HRR genes across the multi-cancer cohort of 950 cases
Cancer | N=142 HRR+ve cases (%) | Major HRR alterations |
Gastrointestinal | 33 (23%) | ATM, ARID1A, BRCA1, PTEN, MRE11 |
Breast | 23 (16%) | BRCA1, PTEN, PALB2, ARID1A, ATM |
Triple-negative breast cancer (TNBC) | 13 (56% of Breast cancer cases with HRR alterations) | BRCA1, BRCA2, PTEN, BAP1, PALB2 |
Female genital tract | 20 (14%) | BRCA1, ARID1A, PTEN, RAD54L |
Lung | 19 (13%) | PTEN, ATM, BRCA1, ARID1A |
Head & neck | 13 (9%) | PTEN, ARID1A, ATM, BARD1, RAD50 |
Sarcoma | 10 (7%) | ATRX, PTEN, BRCA2, PALB2 |
Genitourinary | 10 (7%) | CDK12, BRCA1, PTEN |
Other cancers | 9 (6%) | PTEN, ARID1A, BAP1, RAD50 |
Carcinoma of unknown origin | 5 (4%) | ARID1A, ATRX, PTEN |
Conclusions
CGP identified sBRCA and HRR mutations in wide spectrum of cancers enabling the utility of PARPi as maintenance therapy, hence necessitating sBRCA and HRR testing as standard of care besides germline testing for personalized therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract